XCUR Profile
Exicure, Inc., a pioneering biotechnology firm, focuses on developing innovative therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology. The company's leading research program is centered around SCN9A, a novel therapeutic candidate currently in preclinical stages for the treatment of neuropathic and chronic pain. This approach leverages Exicure's advanced SNA platform, designed to deliver therapeutic nucleic acids with high precision and efficacy.
In addition to its internal research efforts, Exicure has established significant partnerships to expand its therapeutic applications. The company has entered into a collaboration, option, and license agreement with AbbVie Inc., which is focused on the development of SNA-based treatments for hair loss disorders. This partnership aims to harness SNA technology for effective solutions in addressing hair loss conditions, reflecting the versatility and potential of Exicure’s platform.
Furthermore, Exicure has a collaborative agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids targeting rare and complex neurological disorders, specifically Huntington's disease and Angelman syndrome. This collaboration underscores Exicure's commitment to addressing unmet medical needs through its cutting-edge technology, and highlights its role in advancing treatments for challenging genetic conditions.
Founded in 2011 and headquartered in Chicago, Illinois, Exicure, Inc. is at the forefront of biotechnology innovation. The company's focus on SNA technology positions it as a leader in developing targeted and potentially transformative therapies. Through its strategic partnerships and ongoing research, Exicure is advancing the field of genetic medicine and working to deliver novel solutions for patients with severe neurological disorders and hair loss.
|
